Increasing utilization of human T-cell lymphotropic virus (+) donors in liver transplantation: Is it safe?

Transplantation

Volumn 87, Issue 8, 2009, Pages 1180-1190

  Marvin, Michael R ^a,c   Brock, Guy N ^b   Kwarteng, Kwadwo ^b   Nagubandi, Ravi ^a   Ravindra, Kadiyala V ^a   Eng, Mary ^a   Buell, Joseph F ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c JEWISH HOSPITAL   (United States)

Author keywords

Extended criteria donors; Human T cell lymphotrophic virus; Liver transplantation; UNOS data

Indexed keywords

CREATININE;

ADULT; ARTICLE; CONTROLLED STUDY; DEATH; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; RECIPIENT; SAFETY; SURGICAL RISK; SURVIVAL; AGED; DONOR; ETHNIC GROUP; HEPATITIS DELTA VIRUS; HUMAN T CELL LEUKEMIA VIRUS INFECTION; LABORATORY DIAGNOSIS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; STATISTICS; SURVIVAL RATE; SURVIVOR; VIRUS INFECTION;

ADULT; AGED; DELTARETROVIRUS INFECTIONS; ETHNIC GROUPS; FALSE POSITIVE REACTIONS; FEMALE; GRAFT SURVIVAL; HEPATITIS DELTA VIRUS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL RATE; SURVIVORS; TISSUE DONORS; TUMOR VIRUS INFECTIONS;

EID: 65549139300     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819ebf76     Document Type: Article

References (32)

1. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2006; 5: 307.
2. Saab S, Ibrahim A, Surti B, et al. Pretransplant variables associated with quality of life in liver transplant recipients. Liver Int 2008; 28: 1087.
3. Popovic M, Reitz MS, Kalyanaraman VS, et al. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukemia. Nature 1981; 294: 268.
4. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1: 1031.
5. Shames BD, D'Alessandro AM, Sollinger HW. Human T-cell lymphotrophic virus infection in organ donors: A need to reassess policy? Am J Transplant 2002; 2: 658.
6. Gonzalez-Perez MP. Human T-cell leukemia virus type I infection in various recipients of transplants from the same donor. Transplantation 2003; 75: 1006.
7. Zarranz JJ, Rouco I, Gomez-Esteban JC. Human T lymphotropic virus type I (HTLV-1) associated myelopathy acquired through a liver transplant. J Neurol Neurosurg Psychiatry 2001; 71: 818.
8. Toro C, Rodes B, Poveda E, et al. Rapid development of subacute myelopathy in three organ transplant recipeints after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003;75: 102.
9. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783.
10. Wiesner RH, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
11. Klein JP, Moeschberger ML. Survival Analysis. 2nd ed. New York, Springer 2003.
12. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc B 1972; 34: 187.
13. Contal C, O'Quigley J. An application of change point methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999; 30: 253.
14. Araujo AQ, Silva MT. The HTLV-1 neurological complex. Lancet Neurol 2006; 5:1068.
15. Feurer G, Green PL. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene 2005; 24: 5996.
16. Araujo A, Hall WW. Human T-lymphotropic virus type II and neurological disease. Ann Neurol 2004; 56: 10.
17. Holsberg P, Hafler DA. Pathogenesis of diseases induced by human lymphotrophic virus type I infection. N Engl J Med 1993; 328: 1173.
18. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in the incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991-96. JAMA 2000; 284: 229.
19. Levine PH, Dosik H, Joseph EM, et al. A study of adult T-cell leukemia/ lymphoma incidence in central Brooklyn. Int J Cancer 1999; 80: 662.
20. Harrington WJ, Ucar A, Gill P, et al. Clinical spectrum of HTLV-I in south Florida. J Acquir Immune Defic Syndr 1995; 8: 466.
21. Watanabe T. HTLV-1 associated diseases. Int J Hematol 1997; 63: 257.
22. Maloney EM, Cleghorn FR, Morgan OSC, et al. Incidence of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic SyndrHumRetrovirol 1998; 17: 167.
23. Olindo S, Cabre P, Lezin A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol 2006; 63: 1560.
24. Tanabe K, Kitani R, Takahashi K, et al. Long-term results in human T-cell leukemia virus type 1-positive renal transplant recipients. Transplant Proc 1998; 30: 3168.
25. Kawano N, Shimoda K, Ishikawa F, et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a livingdonor liver transplantation. Transplantation 2006; 82: 840.
26. Soyama A, Eguchi S, Takatsuki M, et al. Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation. Liver Transpl 2008; 14: 647.
27. Nakatsuji Y, Sugai F, Watanabe S, et al. HTLV-I associated myelopathy manifested after renal transplantation. J Neurol Sci 2000; 177: 154.
28. Kauffman H, Taranto S. Human T-cell lymphotrophic virus type-1 and organ donors. Transplantation 2003;76: 745.
29. Alkofer B, Kin C, Lo I, et al. Utilization of HTLV infected liver allografts for liver transplantation. Abstract - ASTS Winter Symposium, Solving the Organ Shortage Crisis: 32 Implications of Expanding the Donor Pool, Macro Island, FL, Jan 12-14, 2007.
30. Lo I, Alkofer B, Kin C, et al. Utilization of HTLV serology positive allografts for liver tranpslantation. Abstract - ASTS Winter Symposium, Solving the Organ Shortage Crisis: 32 Implications of Expanding the Donor Pool, Macro Island, FL, Jan 12-14, 2007.
31. Silva MT, Harab RC, Leite AC, et al. Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1- associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection. Clin Infect Dis 2007; 44: 689.
32. Nagubandi R, Brock GN, Ravindra KV, et al. Optimal utilization ofHTLV I/II positive organs-A nationwide survey. Am J Trans 2008; 8: S2: 231.